Skip to main content

Market Overview

Virpax's Liposomal Bupivacaine Candidate Associated With No Neurotoxicity In Animal Studies

Share:
Virpax's Liposomal Bupivacaine Candidate Associated With No Neurotoxicity In Animal Studies
  • Virpax Pharmaceuticals Inc (NASDAQ: VRPX) has announced data from a sciatic nerve preclinical study designed to evaluate Probudur, Virpax's liposomal bupivacaine product candidate.
  • This study's objective was to assess neurotoxicity resulting from a long residence time of a local anesthetic in proximity to the sciatic nerve in rabbits.
  • The rabbit limbs dosed with the liposomal prolonged bupivacaine release (Probudur), at ten times more than free bupivacaine, showed no nerve damage signs.
  • Further, nerves injected with Probudur showed mild signs of inflammation and small residues of the hydrogel in granulomas, indicating a long residence time of the hydrogel at the injection site, but no histopathological signs of nerve damage.
  • Price Action: VRPX shares are up 5.26% at $5.1 during the market trading session on the last check Monday.
 

Related Articles (VRPX)

View Comments and Join the Discussion!

Posted-In: Biotech News Health Care FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com